New and Emerging Tobacco Products: Biomarkers of Exposure and Injury

Friday, February 12, 2016: 8:00 AM-9:30 AM
Marshall Ballroom East (Marriott Wardman Park)
On June 22, 2009, the Family Smoking Prevention and Tobacco Control Act was signed into law, giving the U.S. Food and Drug Administration (FDA) the authority to regulate new and emerging tobacco-derived products. Subsequently there was an obvious need for scientific data to inform FDA’s decision-making about these products. Studies on biomarkers of exposure and injury, and controlled, acute, chronic, and longitudinal exposure studies are being conducted to better define what new and emerging tobacco-derived products do in a variety of preclinical and clinical settings. New and emerging tobacco- and nicotine-derived products now come in a dizzying array of forms – including electronic cigarettes, smokeless tobacco (e.g., snus, snuff, gutkha), shisha for hookah/water pipes, dissolvable lozenges, and nicotine gels –  that contain, deliver, or generate varying amounts of harmful or potentially harmful constituents, making it challenging to predict the biological effects of exposures based solely on traditional cigarette exposure studies. This symposium provides a broad overview of research to identify biomarkers of exposure, biomarkers of injury, and acute and chronic effects in the cardiovascular, pulmonary, and reproductive organ systems resulting from exposure to new and emerging tobacco products.
Daniel Conklin, University of Louisville
Judith Zelikoff, New York University School of Medicine
Neal Benowitz, University of California, San Francisco
Ilona Jaspers, University of North Carolina, Chapel Hill
Pulmonary Effects of Exposure to Tobacco Smoke and New Tobacco Products